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Are the patients afraid of opioids?
Pilot study of the patients
with chronic cancer
and non-malignant pain
Abstract
Background. Chronic pain is a major public health issue. Opioids have an important role in the manage-
ment of chronic cancer and non-cancer pain. Unfortunately, beliefs and myths about opioids are a serious
obstacle to using them in pain relief.
Material and methods. The study involved 28 patients who suffered from chronic cancer or non-cancer
pain. The functional status was measured using Karnofsky Performance Scale and Edmonton Symptom
Assessment System. Each patient was asked to complete a survey consisting of three parts, which deter-
mined patients medical characteristics, knowledge of analgesic drugs and the fears of using opioids.
Results. Our study showed that over half of the surveyed patients (53%) had doubts about starting the
opioids treatment. They were afraid of taking morphine and the patients who used tramadol feared of
changing it into morphine. The most common reason given by the patients was the fear of addiction and
death, which were believed to be associated with using opioids. Other reasons included: the fear of side
effects and/or unsatisfactory result of pain relief.
Conclusion. Our research suggests that patients are afraid of taking opioids, especially morphine. The
results of this pilot study vote for the need of larger survey on patients' attitude to the treatment with
opioids for pain management.
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Introduction
Opioids for moderate to severe pain have been
central to the management of cancer pain since
publication of the World Health Organization (WHO)
guidelines and three-step analgesic ladder [1]. They
are also recognized as having an important role in
the management of chronic non-malignant pain
[2]. Despite the fact that the last few decades have
seen a good scientific evidence for use of the opio-
ids in pain management, there is a lot of fear of
using these drugs. Beliefs and myths about opio-
ids, particularly morphine, are rooted in their use
and misuse throughout the history [3]. Opiopho-
bia, defined as the irrational fear and prejudice of
using opioids, can be a main cause of wrong pain
management.
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The aim of this pilot study was to assess how the
opioids are perceived by the patients with chronic
pain, define their fear of using them and their  knowl-
edge of analgesic drugs.
We were also interested whether the family situ-
ation, education, sex and physical condition have
any influence on perceiving opioids.
Material and methods
The study protocol was accepted by the Ethics
Committee of the Nicolaus Copernicus University,
Collegium Medicum Bydgoszcz in Poland. Before
the trial each patient signed an informed consent.
The study involved patients from palliative care
units or provided with hospice home care who
suffered from chronic cancer or non-malignant
pain. Their functional status was measured using
Karnofsky Performance Scale (0–100) and multi-
ple symptoms were evaluated according to The
Edmonton Symptom Assessment System (ESAS)
[4, 5]. Each patient was asked to complete a sur-
vey consisting of three parts (Figure 1). The sur-
veys were carried out by the authors of the study
during home visits or while staying in palliative
units. The first part contained the general infor-
mation to define the patients medical characteris-
tics. The second part measured the level of pa-
tients' knowledge of the analgesics and their hab-
its of using them. The third part was to determine
the fear of using opioids.
Results
The study involved 28 patients. Their demograph-
ic and clinical data are  presented in the Table 1. The
multiple symptoms evaluation by ESAS is shown in
the Table 2.
Figure 1. The questionnaire used in the study
I. PART
Including general information about a patient (name, date of birth, sex, address, telephone number, family situation,
education) and medical characteristics (diagnosis, medications)
II. PART
The patients were asked questions:
1. What, in your opinion, is the strongest analgesic drug?
2. What  side effects can paracetamol cause if taken in bigger doses than suggested in the information leaflet or
by the doctor ?
A) There are no side effects
B) Side effects are not dangerous
C) Side effects are harmful
D) I don't know
3. Do you always read the attached information about drugs before taking them or ask your doctor about it?
Yes No
4. Where do you get the information about medication from?
A) A doctor or a pharmacist
B) I read the information leaflet
C) Other (eg. literature, internet): ……………
III. PART
Are you afraid of taking opioids? (we chose the one(s) currently used by a patient)
Yes No
If the answer was positive, they were asked to define their fears.
Additional question for patients using tramadol
The patients using tramadol were asked whether they would be afraid of changing it into a stronger opioid (morphine/
fentanyl/ methadone/ buprenorphine).
Would you be afraid of changing tramadol into morphine/ fentanyl/ methadone/ buprenorphine
Yes No
If the answer was positive, they were asked to define their fears.
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In the patients' opinion the strongest analgesic
was tramadol (21%) but 25% of them could not
answer this question. Other often listed drugs in-
cluded: morphine (20%), ketoprofen (17%), diclofen-
ac (6%), paracetamol (6%), ibuprofen (3%). None of
the patients listed transdermal opioids (fentanyl,
buprenorphine) as the strong analgesics.
The answers to the second question showed that
51% of the patients didn't know whether paraceta-
mol causes any side effects or not. 21% claimed it
did and assessed as dangerous and potentially harm-
ful medication. 14% said that paracetamol caused
side effects but posed no threat to health. 14%
stated there were no side effects at all.
Almost all patients (93%) said they read the in-
formation leaflet about drugs. When asked about
their source of information, 36% named a doctor or
a pharmacist, 36% information leaflet  and 28%
said both.
Over half of the surveyed patients (53%) had
doubts about starting the opioids treatment. They
were afraid of taking morphine (50%) and the pa-
tients who used tramadol feared of changing it into
morphine (62%)). The most common reason given
by the patients was the fear of addiction. “Mor-
phine is addictive. I'll become an addict” claimed
48% of the patients. The fear of death was the sec-
ond most common. 40% of the patients believed
that morphine signified “the end” , meant they were
going to die soon and was used to shorten life.
Other reasons included: the fear of side effects (“Mor-
phine causes lots of side effects.”) (4%), the fear of
unsatisfactory result (“What if it is not going to
help?”)(4%) and indefinite fear (“I'm afraid but I
don't know why.”)(4%).
Discussion
The patients included in our study were in rela-
tively good physical condition (as Karnofsky Perfor-
mance Scale shows) with good control of symptoms
(ESAS). Unfortunately too low number of surveyed
patients made it impossible to assess the relation
between the performance status or the intensity of
Table 1. Patients medical characteristics
Variable
Total number od patients 28
Gender
Male 15
Female 13
Age (average) 65.0 ± 11.01
Clinical diagnosis
Cancer type
Lung 7
Prostate 3
Colon 3
Stomach 2
Uterine 2
Larynx 2
Unknown primary 2
Pharynx 1
Adrenal 1
Ovarian 1
Hodgkin’s disease 1
Breast 1
Melanoma 1
Non-malignant disease
Syringomyelia 1
Medication
Morphine 12
Morphine + fentanyl 5
Tramadol 9
Morphine + buprenorphine 1
Buprenorphine 1
Karnofsky Performance Scale 50 ± 43.3–58.1
(median ± 95%CI)
Table 2. Multiple symptom evaluation by The Ed-monton Symptom Assessment System (ESAS)
Measured parameter Average Median Minimum Maximum
Pain 2,36 1,5 0 8
Tiredness 4,36 5 0 9
Nausea 1,64 0 0 10
Depression 3,36 3 0 10
Anxiety 2,86 0,5 0 10
Drowsiness 4,32 5 0 10
Appetite 5,39 5,5 0 10
Wellbeing 4,64 5 0 10
Shortness of breath 1,18 0 0 10
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symptoms and the existence of doubts connected
with opioids management. It was also difficult to
say whether family situation, education or sex are of
any influence on perceiving opioids. This is a pilot
study and it will be continued among a greater num-
ber of patients what will enable us to determine
those relations.
The study showed that over half of the patients
(53%) had doubts about taking opioids. They are
afraid of using morphine (50%) and changing tram-
adol into morphine (62%). Surprisingly, the patients
were not afraid of transdermal analgesics because
the patches were not recognized by them as the
strong opioid preparations. Therefore we can as-
sume that the word “morphine”, and not the inten-
sity of analgesic action of certain opioids, appears
to be the reason for patients' fear.
The patients were mostly afraid of getting ad-
dicted (48%). Therefore it may be challenging for
doctors to create a good way of communicating
with patients. It is crucial that patients are informed
that opioids used for pain relief in adequate doses
and timing do not lead to addiction. The results of
this pilot study show that morphine is often recog-
nized as associated with imminent death (40%).
Therefore, it is mandatory to make the patients un-
derstand that morphine administration is used for
pain relief, but not to shorten life. Informing pa-
tients about the possibility of controlling side ef-
fects is equally important.
The study investigated the level of patients' knowl-
edge of analgesics. Interestingly, 32% of patients
pointed out the non-opioids as the strongest drugs
for pain relief (26% non-steroidal anti-inflammatory
drugs, 6% paracetamol). Only 20% of patients indi-
cated morphine. At the same time half of the sur-
veyed were afraid of morphine. However, they did
not fear of morphine as a strong analgesic because
they did not usually associate it with a kind of anal-
gesic medicine at all. They perceive it as an addictive
substance shortening life. What is more, none of
the patients listed transdermal opioids (fentanyl,
buprenorphine) as the strong analgesics. It may be
related to the way of administering these drugs.
The research proved that the patients’ aware-
ness of analgesics is not sufficient.
The lack of knowledge of analgesic action and
even more often the incorrect information about
some analgesic drugs are the barriers to adequate
pain management. Other factors being obstacles to
successful pain control are professionals' not suffi-
cient knowledge of pain treatment and the influ-
ence of national regulations [6, 7]. The International
Narcotics Control Board (INCB) [8] lists the negative
perception about opioids among medical profes-
sionals as one of the reasons for their inadequate
use. That is why we would also like to make a survey
among them as a part of our future study.
Conclusion
This pilot study enabled us to make initial esti-
mations concerning patients’ fear of opioids treat-
ment. Our research suggests that patients were afraid
of taking opioids, especially morphine. The results
of this pilot study indicate that it ought to be con-
tinued in a bigger group of patients.
Thus it will be possible to determine the relation
between the performance status or the intensity of
symptoms, family situation, education or sex and
the existence of doubts connected with opioids man-
agement.
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